Vitamin D (VitD) 4 insufficiency/deficiency exists in epidemic proportions in the general population and is manifested by calcium malabsorption, secondary hyperparathyroidism, muscle weakness, and/or osteoporosis or osteomalacia. Low dietary intake of VitD, lack of exposure to sunlight, and other variables are contributing factors. Described as a "pseudo" vitamin, VitD exists in 2 forms: cholecalciferol (vitamin D 3 ) produced in skin via a photochemical reaction with 7-dehydrocholesterol (1 ); and ergocalciferol (vitamin D 2 ) derived from plants and used as a supplement. The clinical significance of the chemical differences between the 2 forms and their respective metabolites remains unresolved, although one study reported that ergocalciferol is less effective than cholecalciferol in humans (2 ) .
Clinical laboratory scientists have a diverse array of VitD testing methods from which to choose. Many of these assays have been reported in review articles (3) (4) (5) , the most recent in 2004; however, additional assays have been introduced since that time. Briefly, current competitive protein-binding assays (CPBAs) for 25- (10, 11 ) , required gradient elution (12 ) , or analyzed crude serum extracts that, when injected on an HPLC column, compromised resolution and column life (9 ) . Recently, commercial reagent sets that measure 25(OH)D 3 but not 25(OH)D 2 have been marketed by Immundiagnostik AG (normalphase column) and Chromsystems (reversed-phase column).
Highly selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods described in the literature include fast atom bombardment LC-MS/MS with Cookson-type reagents (13 ) and isotope-dilution electrospray LC-MS/MS (14 -16 ) , which is an attractive technique because it enables analysis of crude serum extracts within short run times to gain potentially high throughput. To achieve speed, methods may force elution of metabolites and internal standard under essentially one peak. Under these circumstances, ion suppression can be a major problem (17 ) (18 ) . Without chromatographic resolution of the 2 compounds, the epimer could mistakenly be reported as 25(OH)D 3 . Although LC-MS/MS can be the superior method, most clinical laboratories hesitate to embrace the technique because of the substantial cost and need for highly trained operators.
Here we describe a selective validated HPLC method for measurement of 25(OH)D 3 and 25(OH)D 2. The method was developed in response to the inconsistency or restrictions of commercial assays (3 ) and the clinical concern that an individual may have received a diagnosis of low or normal VitD status depending on which analytical method and laboratory are used (19 ) . Additionally, we compare results for patient samples tested by 4 current methods. Physicians, clinical laboratory scientists, and manufacturers of VitD reagents may find this information useful.
Materials and Methods
The VitD metabolites 25 (Millipore) . The precipitation reagent contained the internal standard laurophenone (400 g/L) in CH 3 CN and was stored in an amber bottle. Strata-X (surface-modified styrene-divinylbenzene resin) 60-mg (1 mL) extraction cartridges were from Phenomenex. An automated extraction instrument, the Gilson ASPEC XL4 (Gilson Instruments), consisted of a 4-syringe pump module and a 4-needle sampler module with four 2-way solvent ports. Areas in the sampler racks were defined as the sample zone, reagent zone, result zone, and a disposable extraction column (DEC) zone. Acetonitrile was delivered via solvent ports. Acetonitrilewater (35:65 by volume) was stored and delivered from tubes within the reagent zone. The main reservoir contained water. The solvent evaporator was a Turbo Vap TM LV (Caliper Life Sciences). Temperature was set at 35°C, nitrogen flow was adjusted to 10 psi on the instrument gauge, and the typical drying time setting was 25 min. The HPLC unit was an integrated system with a UV3000 detector set at 275 nm, a P4000 pump set at 1.2 mL/min, an AS2000 autosampler, and a SCM1000 solvent system, all from Thermo Separation Products. A silica-saturator column [250 ϫ 4.6 mm (i.d.) stainless steel column; Alltech] packed with ICN silica gel (particle size, 63-100 m; MP Biochemicals) was installed in the oven between the pump and injector and is necessary here to prevent deterioration of the analytical column (20 ) . Individual calibrator stock solutions (40 mg/L) of each metabolite were prepared in ethanol, and the concentration was verified on a Beckman DU 7500 spectrophotometer, using molar absorptivities at 265 nm (1-cm pathlength) of 19 400 and 18 300 for 25(OH)D 2 and 25(OH)D 3 , respectively (5 ) . From these primary stocks, we prepared a dilute combined stock solution of the compounds at 10 000 g/L each in ethanol, which was stable for at least 1 year at Ϫ20°C. We then prepared multiple working calibrators in the range of 5-200 g/L for each of the 2 VitD metabolites combined in a drug-free serum pool. The concentrations of endogenous 25(OH)D 3 and 25(OH)D 2 present in the pool were taken into account when assigning the final concentration to the calibrator. Serum calibrators were stored frozen at Ϫ20°C in 10-mL glass vials sealed with Teflon-lined caps (Quorpak TM ; Fisher Scientific) and were stable for at least 6 months. Controls were prepared and used in the same manner. Commercial lyophilized serum controls were customprepared for us by Utak Laboratories, Inc. Reconstituted Utak controls and thawed calibrators/controls were stable for at least 1 month stored at 4°C.
Clinical Chemistry 52, No. 6, 2006 procedure To prepare samples, we dispensed 2 mL of precipitation reagent with internal standard into a 13 ϫ 100 mm disposable glass test tube; we then added 1.0 mL of serum (calibrator, control, or patient sample) to the tube without mixing of contents to avoid "balling" of the protein. The tube was allowed to sit for 5 min at room temperature, after which it was vortex-mixed for 10 s to obtain a flocculent precipitate. After another 5-min wait, the tube was vortex-mixed and centrifuged at 2000g for 10 min. The clear supernatant was decanted into a 10 ϫ 75 mm disposable glass test tube, which was then transferred to the sample zone of the ASPEC XL4 and protected from exposure to natural sunlight to prevent degradation of analytes. The extraction conditions are defined in Table 1 . The XL4 processed 4 samples simultaneously and unattended in ϳ15 min. The unit sequentially conditioned the Strata-X cartridge in the DEC zone with 2.0 mL of CH 3 CN followed by 2.0 mL of 35:65 CH 3 CN-water; added 1.0 mL of water to each extract; transferred 3.5 mL of extract mixture to the DEC; rinsed the DEC with 2.0 mL of 35:65 CH 3 CN-water; and eluted the Strata-X cartridge in the DEC zone with 2.0 mL of CH 3 CN. The eluate was dried at 35°C under a stream of nitrogen; the dry extract was then reconstituted with 150 L of ethyl acetate-CH 3 CN (5:95 by volume) and vortex-mixed for 5 s. Water (110 L) was then added to the tube, and the contents were vortexmixed for 5 s. The sample was centrifuged at 2000g for 10 min to settle the precipitate. The clear liquid was transferred to a glass microvial insert positioned in an ambercolored vial. The sample was capped and placed in the autosampler unit of the HPLC. The extract was stable for at least 3 days at room temperature. The processor software calculated relative retention time for peak identification and peak-height ratio for quantification.
Results
Typical HPLC chromatograms of calibrator and patient sample extracts are illustrated in Fig. 1 . Late-eluting peaks were observed at 29 and 37 min; however, chromatographic runs can be shortened by overlapping (injecting) samples at intervals, on average, of every 16 -17 min. In these conditions, these late-eluting peaks are "placed" in an area in which they do not obstruct important analyte peaks in succeeding chromatograms.
Between-run precision data were calculated from 5 control sera (n ϭ 20 for each). . In each case, x represents the concentration added to a serum sample and y the analytical result. The lower limit of detection was the lowest concentration that gave a signalto-noise ratio of 3 or greater, and the LLQ was the lowest concentration that gave a signal-to-noise ratio of 10 or greater. In a precision study (n ϭ 10) using calibrators at concentrations of 4 and 6 g/L for both 25(OH)D 2 and 25(OH)D 3 , the signal-to-noise ratios were Ͼ14 and the CVs were 7.1%-15%. We therefore selected 5 g/L as the LLQ.
interferences
When we used Vacutainer TM SST tubes (Becton Dickinson) or Vacuette TM tubes (Greiner), the resulting sera contained substances that appeared as chromatographic Fig. 2) . Conversely, we observed significant disparity between the HPLC and the Nichols Advantage CPBA chemiluminescent assay for total 25(OH)D concentrations (Fig. 3A) . Regression analysis yielded the following: y ϭ 1.00x ϩ 3.6 g/L (S y͉x ϭ 32.7 g/L; r ϭ 0.6823; n ϭ 54). 
Discussion technical considerations
The analysis of VitD metabolites presents a unique challenge. The highly lipophilic compounds strongly associate with VitD-binding protein (VDBP), a bond that must be broken to release the metabolites for efficient liquidliquid or solid-phase extraction. Moreover, endogenous lipids readily coextract with the metabolites and produce visibly "dirty" extracts that can foul the HPLC column and distort chromatographic peak shape. Clean-up steps are essential for a reliable, stable HPLC method (4 ). Light, especially direct natural sunlight, will rapidly degrade the internal standard and 25(OH)D metabolites. Moreover, care must be exercised to prevent instability of the internal standard during the evaporation step. Temperatures in excess of 35°C and/or extended periods under a nitrogen stream after solvent evaporation can decrease recovery of the internal standard. Furthermore, recovery of the internal standard will differ with changes in volume of the serum tested and when diluted serum is used. Accordingly, the volumes of calibrators and controls extracted must be the same as the volume tested for patient samples. The smallest sample size for this method is 0.5 mL; the LLQ would then be 10 g/L. Laurophenone was chosen as the internal standard because it separates from the 25(OH)D metabolites and other endogenous compounds. We evaluated a series of compounds that are structurally similar to the 25(OH)D metabolites but found no good candidates.
Several attempts have failed to standardize, or at least harmonize, 25(OH)D results from different laboratories, which suggests a complex problem as the root source of variability. A starting point would be the production of certified pure 25(OH)D 3 and 25(OH)D 2 substances in quantities that can be easily measured gravimetrically. Historically, the convention has been to assign a value to stock calibrator solutions of 25(OH)D 3 and 25(OH)D 2 through spectrophotometric analysis and calculations using molar absorptivity factors. Much would be gained with the availability of accurate calibrators, perhaps through the NIST. Equally important would be the availability of commercial control products containing both 25(OH)D 3 and 25(OH)D 2 . Likewise, a serum product Some VDBP-based assays forgo the traditional liquidliquid or solid-phase sample clean-up for convenience and to minimize the need for manual intervention. Unfortunately, reports of inaccuracy have brought into question the reliability of the VDBP-based assays (26, 27 ) .
In 1985, the first "valid" RIA for circulating 25(OH)D was introduced (28 ) . A 3 H-labeled 25(OH)D tracer was used initially but was replaced by an 125 I-labeled 25(OH)D tracer in 1993. The Hollis RIA was subsequently offered by Diasorin, which later incorporated chemiluminescent detection on the Liaison platform. Both assays use the same antibody but when compared gave different results (29 ) . Our data both confirm and contradict other investigators' observations, which points to user reliance on the accuracy of the procedures used in the evaluation. Maunsell et al. (16 ) reported no concentration-dependent difference between the Diasorin RIA and their LC-MS/MS method for 160 patients, and Fenske et al. (30 ) stated that the Diasorin RIA and an LC-MS/MS method compared very closely. Compounding the problems associated with the Nichols Advantage CPBA and Diasorin RIA are reports that minimize the inconsistencies of these assays. Interestingly, enough disparity was observed when values for individual samples were compared to generate uncertainty concerning the accuracy of the RIA. Close examination of some reports revealed that a reference method (i.e., HPLC or LC-MS/MS) was lacking in some comparison studies (24, 27, 29, 31 ) . Even more confusing and misleading are studies in which a method with known inaccuracy was used as the comparison method (24 ) . In the midst of this conundrum, attempts have been made to develop an interpretive reference interval unique to a particular method regardless of the inaccuracies displayed (19, 30 ) . Inaccurate methods give inaccurate results and thereby bring into question the actual benefit to patients and the costs associated with error-prone assays. Appropriately, there is a demand for clinically feasible validated commercial assays. A future challenge is the integration of essential pretreatment/separation processes into instrumentation. Early CPBA methods obtained selectivity through time and effort dedicated to isolating 25(OH)D from complex matrices before the actual analysis (32 ) . Appropriate automation of sample pretreatment would be a step forward in achieving comparable accuracy.
Our laboratory provides 25(OH)D testing 5 days a week and meets the needs of a medium-size university hospital. Daily testing is performed by 1 of 6 analysts on a rotating basis. Extractions are routinely performed during the day shift, and samples are analyzed overnight by an unattended HPLC to obtain results the next morning. Currently, we can process up to 50 samples per day. The assay has been in use for 10 months, and we typically assay an average of 600 samples each month. Moreover, 2 laboratories outside of our hospital have successfully replicated our method.
In summary, the variability among current commercial immunoassays and the inaccuracy of the Nichols Advantage CBPA in measuring 25(OH)D 2 and 25(OH)D 3 bring into question the benefit these assays have for patients. In light of these observations, validated LC-MS/MS and HPLC procedures would be the preferred techniques for measuring these 2 metabolites.
